GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00320929 | Prostate | BPH | positive regulation of protein binding | 28/3107 | 85/18723 | 1.65e-04 | 1.43e-03 | 28 |
GO:00451164 | Prostate | BPH | protein neddylation | 10/3107 | 18/18723 | 1.87e-04 | 1.55e-03 | 10 |
GO:00487626 | Prostate | BPH | mesenchymal cell differentiation | 61/3107 | 236/18723 | 1.88e-04 | 1.55e-03 | 61 |
GO:00454447 | Prostate | BPH | fat cell differentiation | 59/3107 | 229/18723 | 2.60e-04 | 2.04e-03 | 59 |
GO:00506796 | Prostate | BPH | positive regulation of epithelial cell proliferation | 54/3107 | 207/18723 | 3.33e-04 | 2.52e-03 | 54 |
GO:000974915 | Prostate | BPH | response to glucose | 55/3107 | 212/18723 | 3.42e-04 | 2.55e-03 | 55 |
GO:00604854 | Prostate | BPH | mesenchyme development | 71/3107 | 291/18723 | 3.82e-04 | 2.81e-03 | 71 |
GO:00310566 | Prostate | BPH | regulation of histone modification | 42/3107 | 152/18723 | 4.09e-04 | 2.97e-03 | 42 |
GO:19019832 | Prostate | BPH | regulation of protein acetylation | 25/3107 | 77/18723 | 4.62e-04 | 3.32e-03 | 25 |
GO:00510906 | Prostate | BPH | regulation of DNA-binding transcription factor activity | 100/3107 | 440/18723 | 4.71e-04 | 3.37e-03 | 100 |
GO:004682516 | Prostate | BPH | regulation of protein export from nucleus | 13/3107 | 30/18723 | 5.11e-04 | 3.62e-03 | 13 |
GO:00066118 | Prostate | BPH | protein export from nucleus | 20/3107 | 57/18723 | 5.46e-04 | 3.82e-03 | 20 |
GO:00330023 | Prostate | BPH | muscle cell proliferation | 61/3107 | 248/18723 | 7.61e-04 | 5.02e-03 | 61 |
GO:00486605 | Prostate | BPH | regulation of smooth muscle cell proliferation | 47/3107 | 180/18723 | 7.63e-04 | 5.03e-03 | 47 |
GO:20007562 | Prostate | BPH | regulation of peptidyl-lysine acetylation | 21/3107 | 63/18723 | 8.71e-04 | 5.62e-03 | 21 |
GO:001593110 | Prostate | BPH | nucleobase-containing compound transport | 55/3107 | 222/18723 | 1.12e-03 | 6.97e-03 | 55 |
GO:00517752 | Prostate | BPH | response to redox state | 8/3107 | 15/18723 | 1.21e-03 | 7.41e-03 | 8 |
GO:00486595 | Prostate | BPH | smooth muscle cell proliferation | 47/3107 | 184/18723 | 1.26e-03 | 7.62e-03 | 47 |
GO:19040353 | Prostate | BPH | regulation of epithelial cell apoptotic process | 28/3107 | 96/18723 | 1.46e-03 | 8.69e-03 | 28 |
GO:00510286 | Prostate | BPH | mRNA transport | 35/3107 | 130/18723 | 1.93e-03 | 1.10e-02 | 35 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
F7 | SNV | Missense_Mutation | novel | c.308N>A | p.Ser103Tyr | p.S103Y | P08709 | protein_coding | tolerated(0.17) | benign(0.028) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
F7 | SNV | Missense_Mutation | | c.729N>G | p.Ile243Met | p.I243M | P08709 | protein_coding | deleterious(0.04) | benign(0.157) | TCGA-AN-A0AM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
F7 | SNV | Missense_Mutation | novel | c.1132N>A | p.Gly378Arg | p.G378R | P08709 | protein_coding | tolerated(0.22) | benign(0) | TCGA-AR-A2LJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
F7 | SNV | Missense_Mutation | rs749760143 | c.973N>A | p.Glu325Lys | p.E325K | P08709 | protein_coding | tolerated(0.05) | probably_damaging(0.933) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
F7 | insertion | Frame_Shift_Ins | novel | c.731_732insGGGAAAATGGGCAGGTCAGC | p.Asn244LysfsTer28 | p.N244Kfs*28 | P08709 | protein_coding | | | TCGA-AN-A0AM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
F7 | insertion | Frame_Shift_Ins | novel | c.757_758insGCAA | p.His253ArgfsTer29 | p.H253Rfs*29 | P08709 | protein_coding | | | TCGA-BH-A0HY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | taxotere | CR |
F7 | insertion | In_Frame_Ins | novel | c.759_760insCCCAAGGCCGAATTGTGGGGGGCAAGG | p.His253_Cys254insProLysAlaGluLeuTrpGlyAlaArg | p.H253_C254insPKAELWGAR | P08709 | protein_coding | | | TCGA-BH-A0HY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | taxotere | CR |
F7 | SNV | Missense_Mutation | | c.475N>C | p.Glu159Gln | p.E159Q | P08709 | protein_coding | deleterious(0.04) | benign(0.115) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
F7 | SNV | Missense_Mutation | novel | c.348N>C | p.Gln116His | p.Q116H | P08709 | protein_coding | deleterious(0.02) | probably_damaging(0.961) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
F7 | SNV | Missense_Mutation | | c.160N>A | p.Val54Ile | p.V54I | P08709 | protein_coding | tolerated(0.2) | benign(0.01) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | Vatreptacog alfa (activated) | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | Factor viia | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | Recombinant factor VIIa PEGylated liposomal | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | F-7TG | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | BAX-817 | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | inhibitor | 178103166 | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | CB-813 | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | Activated recombinant FVII-albumin fusion protein | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | inhibitor | 252166701 | | |
2155 | F7 | ENZYME, DRUGGABLE GENOME, PROTEASE | | Eptacog alfa intravenous | | |